Turn Biotechnologies

📍 Mountain View, United States🗓 Founded 2018👥 18 employees💰 Last funded Jun 2024
Biotechnology🌐 turn.bio
Website LinkedIn
Aging has been called “the emperor of all maladies.” Turn Bio’s goal is to address multiple aging-related indications using a single powerful reprogramming therapy that turns old cells young again, aiding in the rejuvenation of an aged human body. In 2013, a paper in Cell (The hallmarks of aging, López-Otin et al.,) proposed nine key “Hallmarks of Aging” that are causes of the general phenotype we refer to as “aging.” Our team recognized that it would be necessary to “turn back the clock” on each of these hallmarks and so set out to develop the technology to do just that. The task was achieved by a using a proprietary cocktail of transiently-administered rejuvenation factors that have now been shown to reverse eight of the nine hallmarks. Join us as we embark on the task to "turn back time."​
4
Total investors
1
Early stage
0
Mid stage
3
Late stage
2018
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
2
Singapore
1
Canada
1
Investor activity2019–2024 · investors recorded per year
2019120243
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Turn Biotechnologies?
Turn Biotechnologies has 4 investors on record on gritt.io, including 1 early-stage backers and 3 late-stage investors.
When did Turn Biotechnologies last raise funding?
The most recent investment in Turn Biotechnologies recorded on gritt.io was in June 2024.
When was Turn Biotechnologies founded?
Turn Biotechnologies was founded in 2018.
What industry is Turn Biotechnologies in?
Turn Biotechnologies operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Turn Biotechnologies based?
Turn Biotechnologies is headquartered in Mountain View, United States.